These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20412325)

  • 1. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis.
    Suzuki K; Kirikoshi H; Yoneda M; Mawatari H; Fujita K; Nozaki Y; Takahashi H; Abe Y; Inamori M; Shimamura T; Kobayashi N; Kubota K; Saito S; Nakajima A
    Hepatol Res; 2010 Jul; 40(7):693-700. PubMed ID: 20412325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation.
    Oliva MR; Mortele KJ; Segatto E; Glickman JN; Erturk SM; Ros PR; Silverman SG
    J Comput Assist Tomogr; 2006; 30(1):37-43. PubMed ID: 16365570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver - a human galactose positron emission tomography study.
    Eriksen PL; Thomsen KL; Larsen LP; Grønbaek H; Vilstrup H; Sørensen M
    Aliment Pharmacol Ther; 2019 Jul; 50(1):84-92. PubMed ID: 31099410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis.
    Ismaiel A; Jaaouani A; Leucuta DC; Popa SL; Dumitrascu DL
    Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease.
    Masuda K; Ono M; Fukumoto M; Hirose A; Munekage K; Ochi T; Okamoto N; Akagi N; Ogawa Y; Saibara T
    Hepatol Res; 2012 Mar; 42(3):273-9. PubMed ID: 22251279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
    Yilmaz Y
    Aliment Pharmacol Ther; 2012 Nov; 36(9):815-23. PubMed ID: 22966992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of quantitative 99mTc-phytate scintigraphy to diagnose early-stage non-alcoholic steatohepatitis.
    Kikuchi M; Tomita K; Nakahara T; Kitamura N; Teratani T; Irie R; Yokoyama H; Suzuki T; Yokoyama T; Taguchi T; Tanaka S; Noguchi M; Ohkura T; Hibi T
    Scand J Gastroenterol; 2009; 44(2):229-36. PubMed ID: 18819037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH).
    Wu J; Zhang R; Shen F; Yang R; Zhou D; Cao H; Chen G; Pan Q; Fan J
    Med Sci Monit; 2018 Oct; 24():6946-6967. PubMed ID: 30270343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of non-alcoholic fatty liver disease mediated by YAP.
    Chen P; Luo Q; Huang C; Gao Q; Li L; Chen J; Chen B; Liu W; Zeng W; Chen Z
    Hepatol Int; 2018 Jan; 12(1):26-36. PubMed ID: 29330836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
    Wong VW; Wong GL; Choi PC; Chan AW; Li MK; Chan HY; Chim AM; Yu J; Sung JJ; Chan HL
    Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests.
    Culafic M; Vezmar Kovacevic S; Dopsaj V; Stulic M; Vlaisavljevic Z; Miljkovic B; Culafic D
    Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31163711
    [No Abstract]   [Full Text] [Related]  

  • 17. Simultaneous MR quantification of hepatic fat content, fatty acid composition, transverse relaxation time and magnetic susceptibility for the diagnosis of non-alcoholic steatohepatitis.
    Leporq B; Lambert SA; Ronot M; Vilgrain V; Van Beers BE
    NMR Biomed; 2017 Oct; 30(10):. PubMed ID: 28678410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of Gd-EOB-DTPA-enhanced MR imaging in the evaluation of simple steatosis and nonalcoholic steatohepatitis.
    Wu Z; Matsui O; Kitao A; Kozaka K; Koda W; Kobayashi S; Ryu Y; Minami T; Sanada J; Gabata T
    J Magn Reson Imaging; 2013 May; 37(5):1137-43. PubMed ID: 23172731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.
    Yoneda M; Mawatari H; Fujita K; Iida H; Yonemitsu K; Kato S; Takahashi H; Kirikoshi H; Inamori M; Nozaki Y; Abe Y; Kubota K; Saito S; Iwasaki T; Terauchi Y; Togo S; Maeyama S; Nakajima A
    J Gastroenterol; 2007 Jul; 42(7):573-82. PubMed ID: 17653654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.